IS7600A - Aðferð til að stuðla að reykbindindi - Google Patents

Aðferð til að stuðla að reykbindindi

Info

Publication number
IS7600A
IS7600A IS7600A IS7600A IS7600A IS 7600 A IS7600 A IS 7600A IS 7600 A IS7600 A IS 7600A IS 7600 A IS7600 A IS 7600A IS 7600 A IS7600 A IS 7600A
Authority
IS
Iceland
Prior art keywords
smoke
promoting
promoting smoke
Prior art date
Application number
IS7600A
Other languages
English (en)
Inventor
H. F. Wong Erik
Original Assignee
Pharmacia & Upjohn Company Llc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Company Llc. filed Critical Pharmacia & Upjohn Company Llc.
Publication of IS7600A publication Critical patent/IS7600A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IS7600A 2002-07-01 2004-12-16 Aðferð til að stuðla að reykbindindi IS7600A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39289302P 2002-07-01 2002-07-01
PCT/US2003/016232 WO2004002463A2 (en) 2002-07-01 2003-06-26 Method of promoting smoking cessation

Publications (1)

Publication Number Publication Date
IS7600A true IS7600A (is) 2004-12-16

Family

ID=30000949

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7600A IS7600A (is) 2002-07-01 2004-12-16 Aðferð til að stuðla að reykbindindi

Country Status (22)

Country Link
US (1) US20040102440A1 (is)
EP (1) EP1534254A2 (is)
JP (1) JP2005531631A (is)
CN (1) CN1665511A (is)
AP (1) AP2004003188A0 (is)
AU (1) AU2003253609A1 (is)
BR (1) BR0312293A (is)
CA (1) CA2491549A1 (is)
EA (1) EA200401584A1 (is)
EC (1) ECSP045517A (is)
HR (1) HRP20041194A2 (is)
IL (1) IL165882A0 (is)
IS (1) IS7600A (is)
MA (1) MA27597A1 (is)
MX (1) MXPA05000296A (is)
NO (1) NO20045535L (is)
OA (1) OA12878A (is)
PL (1) PL373620A1 (is)
RS (1) RS115204A (is)
TN (1) TNSN04267A1 (is)
WO (1) WO2004002463A2 (is)
ZA (1) ZA200410339B (is)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE521512C2 (sv) 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
ATE359075T1 (de) 2002-12-20 2007-05-15 Niconovum Ab Chemisch und physikalisch stabiles teilchenförmiges material enthaltend nikotin und microcrystalline cellulose
RU2350327C2 (ru) 2003-04-29 2009-03-27 Ориксиджен Серапьютикс, Инкорпорэйтд Составы, вызывающие потерю веса
EP1870096A3 (en) * 2003-04-29 2011-04-20 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7884136B2 (en) 2005-06-27 2011-02-08 Biovail Laboratories International S.R.L. Modified-release formulations of a bupropion salt
EP1951212A2 (en) 2005-11-22 2008-08-06 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
JP5694645B2 (ja) 2006-03-16 2015-04-01 ニコノヴァム エービーＮｉｃｏｎｏｖｕｍ Ａｂ 改善された嗅ぎたばこ組成物
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US20070297991A1 (en) * 2006-06-23 2007-12-27 Minu, L.L.C. Neural conduit agent dissemination for smoking cessation and other applications
CA2668885C (en) 2006-11-09 2016-08-02 Orexigen Therapeutics, Inc. Methods for administering weight loss medications
WO2009004621A1 (en) * 2007-07-02 2009-01-08 Technion Research & Development Foundation Ltd. Compositions, articles and methods comprising tspo ligands for preventing or reducing tobacco-associated damage
EP2303025A4 (en) 2008-05-30 2012-07-04 Orexigen Therapeutics Inc METHOD FOR TREATING DIGITAL FAT SWITCHES
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
US20110046116A1 (en) * 2009-08-20 2011-02-24 Cukrowski Walter J Sedative for use during eye surgery
JP2013506678A (ja) * 2009-09-30 2013-02-28 クレイトン ビーリー，ハーラン 体重を維持した禁煙および栄養補助剤
EP3659604A1 (en) 2010-01-11 2020-06-03 Nalpropion Pharmaceuticals, Inc. Methods of providing weight loss therapy in patients with major depression
ES2739503T3 (es) 2010-07-09 2020-01-31 Bioverativ Therapeutics Inc Moléculas de cadena simple procesables y polipéptidos producidos usándolas
PT3730132T (pt) 2012-06-06 2022-08-16 Nalpropion Pharmaceuticals Llc Composição para utilização num método de tratamento de excesso de peso e obesidade em doentes com alto risco cardiovascular
US20160256472A1 (en) * 2013-10-14 2016-09-08 Palmaya Pty Ltd Compositions and methods of administering same
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
EP3082816B1 (en) 2013-12-20 2019-03-20 Indivior UK Limited Intranasal naloxone compositions and methods of making and using same
CN104381577A (zh) * 2014-11-18 2015-03-04 安徽润康保健食品有限公司 一种具有戒烟功能的口香糖
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
CN113631157A (zh) 2019-02-17 2021-11-09 诺拉威尔治疗公司 用于治疗抑郁症和其它病症的组合物和方法
WO2021158957A1 (en) 2020-02-05 2021-08-12 Summit Biosciences Inc. Drug products for intranasal administration and uses thereof
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion
US12565478B1 (en) 2025-01-21 2026-03-03 Axsome Therapeutics, Inc. (S)-2-((S)-(2-ethoxyphenoxy)(phenyl)methyl)-4-nitrosomorpholine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002511414A (ja) * 1998-04-09 2002-04-16 ファルマシア・アンド・アップジョン・カンパニー 神経疾患のための新しい治療
TR200003262T2 (tr) * 1998-05-08 2001-03-21 Pharmacia & Upjohn Company Yeni ilaç bileşimleri
DE60035232T2 (de) * 1999-07-01 2008-02-14 Pharmacia & Upjohn Co. Llc, Kalamazoo (S,S)-Reboxetin zur Behandlung von chronischem Müdigkeits-Syndrom
DE10004547A1 (de) * 2000-02-02 2001-08-09 Liedtke Pharmed Gmbh Verfahren zur selektiven Verabreichung zentralnervös aktiver Stoffe

Also Published As

Publication number Publication date
HRP20041194A2 (en) 2005-06-30
EA200401584A1 (ru) 2005-08-25
EP1534254A2 (en) 2005-06-01
US20040102440A1 (en) 2004-05-27
TNSN04267A1 (fr) 2007-03-12
WO2004002463A3 (en) 2004-02-19
ECSP045517A (es) 2005-03-10
BR0312293A (pt) 2005-04-12
CA2491549A1 (en) 2004-01-08
ZA200410339B (en) 2006-07-26
CN1665511A (zh) 2005-09-07
MXPA05000296A (es) 2005-08-19
WO2004002463A2 (en) 2004-01-08
OA12878A (en) 2006-09-15
AU2003253609A1 (en) 2004-01-19
MA27597A1 (fr) 2005-11-01
JP2005531631A (ja) 2005-10-20
AP2004003188A0 (en) 2004-12-31
NO20045535L (no) 2005-01-27
RS115204A (sr) 2007-02-05
PL373620A1 (en) 2005-09-05
IL165882A0 (en) 2006-01-15

Similar Documents

Publication Publication Date Title
IS7600A (is) Aðferð til að stuðla að reykbindindi
BRPI0313238A2 (pt) método
DE60315041D1 (de) Bohrverfahren
DE60327022D1 (de) Standortsberechnungsverfahren
FI20022084L (fi) Menetelmä valmistaa sanomalehtipaperia
IS7446A (is) Aðferð til að mynda næriþekjur prímata
FI20021560A0 (fi) Ohjausmenetelmä
PL394821A1 (pl) Sposób wytwarzania kombrestatyn
DK1496194T3 (da) Fremgangsmåde til behandling af en brönd
FI20021531L (fi) Muurausmenetelmä
EP1488046A4 (en) CONSTRUCTION METHODS
NO20023358D0 (no) Metode
PL375785A1 (pl) Sposób utleniania
FI20022033A0 (fi) Kaukokartoitusmenetelmä
FI20022061A0 (fi) Menetelmä ja järjestely rakennuksen muodostamiseen
FR2834776B1 (fr) Trappe de desenfumage
FI20022301L (fi) Asettamismenetelmä
FI20031391A0 (fi) Menetelmä viilun sorvaamiseksi pöllistä
FI20021779L (fi) Kennorakennekokonaisuuksien rakennusmenetelmä
NO20021887D0 (no) Metode
NO20026287D0 (no) Metode
SE0200924D0 (sv) New method
SE0203388D0 (sv) New method
SE0201024D0 (sv) New method
SE0201576D0 (sv) New method